Targeting CBP/p300 – Inhibition vs. Degradation for Potent Anti-Tumor Efficacy
Targeting CBP/p300 – Inhibition vs Degradation for Potent Anti-tumor Efficacy, Drug Discovery Chemistry
Targeting CBP/p300 – Inhibition vs Degradation for Potent Anti-tumor Efficacy
Characterization of the anti-tumor immune activation potential of AUR107, a novel small molecule p300/CBP bromodomain inhibitor
Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers
Targeting cancer with selective CBP/p300 bromodomain inhibitors
Characterization of the anti-tumor immune activation potential of AUR107, a novel small molecule p300/CBP bromodomain inhibitor SITC, Nov 2022
